Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

Phase 2 Recruiting 124 enrolled Korea University Guro Hospital Asia-Pacific Gynecologic Oncology Trials Group · collab Boryung Pharmaceutical Co., Ltd · collab Chong Kun Dang Pharmaceutical · collab Japanese Gynecologic Oncology Group · collab KGOG: Korean Gynaelogical Onology Group, Korea · collab Yonsei University · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.

Timeline

Start: 2023-12-01
Primary completion: 2026-12-28
Completion: 2028-12-28

Publications

Cho HW, Kim HS, Park JY, Lee YY, Lim MC, Lee SJ, Min KJ, Eoh KJ, Lee KB, Kim MK, Song JY, Shim SH, Ji YI, Song YJ, Chang SJ, Kim MK, Abe A, Kobayashi Y, Kajiyama H, Shimada M, Okamoto A, Ng JS, Lee JY. A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067/JGOG 3036/APGOT-OV11). Int J Gynecol Cancer. 2024 Nov 4;34(11):1809-1812. doi: 10.1136/ijgc-2024-005838.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Bevacizumab	Monoclonal antibody	—	—

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

Summary

Timeline

Publications

Drugs

Indications